Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.57 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.55 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.55 |
| ▸ | MMP2 | P08253 | 2/20 | 0.55 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | RAD52 | P43351 | 1/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.48 |
| ▸ | GMNN | O75496 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL887247 | 1.00 | FFAR4 (0.57) | FFAR4FFAR1PSMD14PLA2G1BMMP2 | |
| SCHEMBL19949219 | 1.00 | FFAR4 (0.57) | FFAR4FFAR1PSMD14PLA2G1BMMP2 | |
| SCHEMBL7209288 | 1.00 | FFAR4 (0.57) | FFAR4FFAR1PSMD14PLA2G1BMMP2 | |
| SCHEMBL23188459 | 1.00 | FFAR4 (0.57) | FFAR4FFAR1PSMD14PLA2G1BMMP2 | |
| SCHEMBL4553176 | 1.00 | FFAR4 (0.57) | FFAR4FFAR1PSMD14PLA2G1BMMP2 | |
| SCHEMBL23225808 | 1.00 | FFAR4 (0.57) | FFAR4FFAR1PSMD14PLA2G1BMMP2 | |
| SCHEMBL16074935 | 1.00 | FFAR4 (0.57) | FFAR4FFAR1PSMD14PLA2G1BMMP2 | |
| SCHEMBL21660117 | 1.00 | FFAR4 (0.57) | FFAR4FFAR1PSMD14PLA2G1BMMP2 | |
| SCHEMBL22910843 | 1.00 | FFAR4 (0.57) | FFAR4FFAR1PSMD14PLA2G1BMMP2 | |
| SCHEMBL609589 | 1.00 | FFAR4 (0.57) | FFAR4FFAR1PSMD14PLA2G1BMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1914237-B1 | Phosphonate ester antiviral compounds | UNIV CALIFORNIA (US) | 2014-06-18 | — | — | EP | claimed |
| US-20130045950-A1 | Phosphonate Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-21 | — | — | US | claimed |
| WO-2011011710-A1 | METHODS OF TREATING VIRAL INFECTIONS | CHIMERIX, INC. (US) | 2011-01-27 | — | — | WO | claimed |
| EP-2155257-A1 | METHODS OF REDUCING NEPHROTOXICITY IN SUBJECTS ADMINISTERED WITH NUCLEOSIDE | Chimerix, Inc. (US) | 2010-02-24 | — | — | EP | claimed |
| WO-2008133966-A1 | METHODS OF REDUCING NEPHROTOXICITY IN SUBJECTS ADMINISTERED WITH NUCLEOSIDE | CHIMERIX, INC. (US) | 2008-11-06 | — | — | WO | claimed |
| US-20080103115-A1 | Alkylpropanediol derivatized adefovir; reduced toxicity; osteoporosis, bone metabolism disorders , cancer, viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-05-01 | — | — | US | claimed |
| EP-1914237-A2 | Phosphonate ester antiviral compounds | The Regents of The University of California at San Diego (US) | 2008-04-23 | — | — | EP | claimed |
| US-20070161602-A1 | New phosphonate ester derivatives of purine or pyrimidine antivirals; side effect reduction, less toxic, bioavailability | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2007-07-12 | — | — | US | claimed |
| US-7094772-B2 | guanin-9-yl, adenin-9-yl, 2,6-diaminopurin-9-yl, 2-aminopurin-9-yl or their 1-deaza, 3-deaza, or 8-aza compounds, or cytosin-1-yl - ethoxymethanephosphonic acid derivatives, used to treat osteoporosis and other disorders of bone metabolism, cancer, or viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-08-22 | — | — | US | claimed |
| US-20050176673-A1 | guanin-9-yl, adenin-9-yl, 2,6-diaminopurin-9-yl, 2-aminopurin-9-yl or their 1-deaza, 3-deaza, or 8-aza compounds, or cytosin-1-yl - ethoxymethanephosphonic acid derivatives, used to treat osteoporosis and other disorders of bone metabolism, cancer, or viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2005-08-11 | — | — | US | claimed |
| US-20250243143-A1 | 1,3-Fatty Diol Compounds And Derivatives Thereof | AGAIN BIO APS (DK) | 2025-07-31 | — | — | US | disclosed |
| EP-4554379-A1 | USE OF AN ALKANEDIOL AS HERBICIDE | Apeo - Agronomical Plant Extracts & Essential Oils (BE) | 2025-05-21 | — | — | EP | disclosed |
| US-12304883-B2 | 1,3-fatty diol compounds and derivatives thereof | GENOMATICA, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20250101471-A1 | Microbial Production Of Fatty Diols | AGAIN BIO APS (DK) | 2025-03-27 | — | — | US | disclosed |
| WO-2024013148-A1 | USE OF AN ALKANEDIOL AS HERBICIDE | APEO – AGRONOMICAL PLANT EXTRACTS & ESSENTIAL OILS (BE) | 2024-01-18 | — | — | WO | disclosed |
| EP-2155257-A1 | METHODS OF REDUCING NEPHROTOXICITY IN SUBJECTS ADMINISTERED WITH NUCLEOSIDE | Chimerix, Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008133966-A1 | METHODS OF REDUCING NEPHROTOXICITY IN SUBJECTS ADMINISTERED WITH NUCLEOSIDE | CHIMERIX, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| EP-1879553-A2 | OCULAR THERAPY USING ALPHA-2 ADRENERGIC RECEPTOR AGONISTS HAVING ENHANCED ANTERIOR CLEARANCE RATES | Allergan, Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006122165-A2 | OCULAR THERAPY USING ALPHA-2 ADRENERGIC RECEPTOR AGONISTS HAVING ENHANCED ANTERIOR CLEARANCE RATES | ALLERGAN, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| CN-1414854-A | Phosphonate compounds | UNIV OF CALIFORNIA SAN DIEGO (US) | 2003-04-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176673-A1 | guanin-9-yl, adenin-9-yl, 2,6-diaminopurin-9-yl, 2-aminopurin-9-yl or their 1-deaza, 3-deaza, or 8-aza compounds, or cytosin-1-yl - ethoxymethanephosphonic acid derivatives, used to treat osteoporosis and other disorders of bone metabolism, cancer, or viral infections | ENPP1, ADA, ENTPD5 | FFAR4 4555/4885FFAR1 4139/4885PSMD14 3237/4885 |
| US-20080103115-A1 | Alkylpropanediol derivatized adefovir; reduced toxicity; osteoporosis, bone metabolism disorders , cancer, viral infections | APRT, AASDHPPT, APOBEC3G | FFAR4 704/4885FFAR1 1223/4885PSMD14 1966/4885 |
| US-20130045950-A1 | Phosphonate Compounds | PHPT1, PHOSPHO1, PIK3CA | FFAR4 3559/4885FFAR1 3787/4885PSMD14 3460/4885 |
| US-20250243143-A1 | 1,3-Fatty Diol Compounds And Derivatives Thereof | DGAT1, DGAT2, DSG1 | FFAR4 287/4885FFAR1 115/4885PSMD14 1199/4885 |
| US-12304883-B2 | 1,3-fatty diol compounds and derivatives thereof | DGAT1, DGAT2, DSG1 | FFAR4 287/4885FFAR1 115/4885PSMD14 1199/4885 |
| US-20070161602-A1 | New phosphonate ester derivatives of purine or pyrimidine antivirals; side effect reduction, less toxic, bioavailability | PNP, TYMP, UMPS | FFAR4 1640/4885FFAR1 1988/4885PSMD14 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.